Nektar Therapeutics
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -77.1% | -77.1% | -46.9% |
| FY2022 | -100.4% | -100.4% | -51.8% |
| FY2023 | -210.8% | -210.8% | -69.4% |
| FY2024 | -195.9% | -195.9% | -39.2% |
| FY2025 | -182.6% | -182.6% | -58.5% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -77.1% | -77.1% | -46.9% |
| FY2022 | -100.4% | -100.4% | -51.8% |
| FY2023 | -210.8% | -210.8% | -69.4% |
| FY2024 | -195.9% | -195.9% | -39.2% |
| FY2025 | -182.6% | -182.6% | -58.5% |